A phase I/II study of sorafenib in combination with low dose cytarabine in elderly patients with acute myeloid leukemia or high-risk myelodysplastic syndrome from the National Cancer Institute of Canada Clinical Trials Group: trial IND.186.
about
Emerging therapies for acute myeloid leukemia.Phosphoproteome Analysis Reveals Differential Mode of Action of Sorafenib in Wildtype and Mutated FLT3 Acute Myeloid Leukemia (AML) CellsMolecular therapy for acute myeloid leukaemia.Phase I trial of maintenance sorafenib after allogeneic hematopoietic stem cell transplantation for fms-like tyrosine kinase 3 internal tandem duplication acute myeloid leukemia.Gene mutations and molecularly targeted therapies in acute myeloid leukemia.Inefficiencies and Patient Burdens in the Development of the Targeted Cancer Drug Sorafenib: A Systematic ReviewRapid induction of complete molecular remission by sequential therapy with LDAC and sorafenib in FLT3-ITD-positive patients unfit for intensive treatment: two cases and review of the literatureLinifanib (ABT-869) Potentiates the Efficacy of Chemotherapeutic Agents through the Suppression of Receptor Tyrosine Kinase-Mediated AKT/mTOR Signaling Pathways in Gastric Cancer.FLT3 inhibitors for acute myeloid leukemia: a review of their efficacy and mechanisms of resistance.Novel therapeutics in acute myeloid leukemia.Frontline therapy of AML: should the older patient be treated differently?Outlook and Management of Patients with Myelodysplastic Syndromes Failed by Hypomethylating Agents.Management of Newly Diagnosed Acute Myeloid Leukemia in the Elderly: Current Strategies and Future Directions.Treatment of Relapsed/Refractory Acute Myeloid Leukemia.Molecular targeting in acute myeloid leukemiaA phase I/II study of sunitinib and intensive chemotherapy in patients over 60 years of age with acute myeloid leukaemia and activating FLT3 mutations.Multikinase inhibitors for treating high-risk myelodysplastic syndromes: can this be brought into clinical practice?Use of FLT3 inhibitors in acute myeloid leukemia remission induction or salvage therapy: systematic review and meta-analysis
P2860
Q33576363-DEA42B18-6476-4BDD-BF75-0A10D8BEF7CEQ33882022-32AE77E1-2FE2-46E2-A1A1-1572A2A712EBQ33925672-0D89418A-7616-407C-B394-B6A8B2F5A627Q34620695-EB782C2F-5606-4C25-91D5-6AA94F3F509AQ34647741-82D52619-A719-4C63-AB5F-FEC0163C1E17Q36270115-FBBD4BF8-2C20-43A6-BB69-EDFA36EB008DQ36940606-CC04821B-63A1-4355-B6F4-2C3230390959Q37076592-DE006692-733C-4793-B96A-FA5F148062C5Q38101284-A9D43683-6FD0-4420-9556-7FC1E1E14B91Q38196346-F7F091F2-02FD-4BDD-B821-5C0A58E98AD4Q38212586-DAAD8C31-B641-4CB6-BF64-A502CB430AE0Q38540859-9485114E-3ABE-4E45-B957-49DC4FBA4FB3Q38601723-ADD5943F-20BC-444C-9430-C9E8CA0240FDQ39175665-2CC60E9D-9025-4787-A4A7-D6A5BDEB9C75Q41558732-16452999-941A-4F93-A6D8-07546D277F52Q54281304-6EEFCDDE-B21A-420A-82D3-C326EB5B7D50Q54405942-9610DE50-F3F4-4C23-ACBF-F52A208912A7Q58781994-AAC674D8-B82C-4557-AB6E-4C854FEC741A
P2860
A phase I/II study of sorafenib in combination with low dose cytarabine in elderly patients with acute myeloid leukemia or high-risk myelodysplastic syndrome from the National Cancer Institute of Canada Clinical Trials Group: trial IND.186.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
A phase I/II study of sorafeni ...... l Trials Group: trial IND.186.
@en
A phase I/II study of sorafeni ...... l Trials Group: trial IND.186.
@nl
type
label
A phase I/II study of sorafeni ...... l Trials Group: trial IND.186.
@en
A phase I/II study of sorafeni ...... l Trials Group: trial IND.186.
@nl
prefLabel
A phase I/II study of sorafeni ...... l Trials Group: trial IND.186.
@en
A phase I/II study of sorafeni ...... l Trials Group: trial IND.186.
@nl
P2093
P2860
P921
P1433
P1476
A phase I/II study of sorafeni ...... l Trials Group: trial IND.186.
@en
P2093
Alison Foo
Brian Leber
David A Macdonald
Elizabeth A Eisenhauer
Joseph Brandwein
Sarit E Assouline
Stephen Caplan
Stephen Couban
Wendy Walsh
P2860
P304
P356
10.3109/10428194.2012.737917
P577
2012-11-15T00:00:00Z